Karyopharm Therapeutics Inc. Stock
Karyopharm Therapeutics Inc. is currently one of the favorites of our community with 17 Buy predictions and no Sell predictions.
With a target price of 12 € there is potential for a 2117.29% increase which would mean more than doubling the current price of 0.54 € for Karyopharm Therapeutics Inc..
Our community identified positive and negative aspects for Karyopharm Therapeutics Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Karyopharm Therapeutics Inc. stock. On the other hand our users think that "Unique positioning" could be a problem in the future.
Pros and Cons of Karyopharm Therapeutics Inc. in the next few years
Pros
?
M***** P*******
?
S********** s********
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Karyopharm Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc. | - | - | - | - | - | - | - |
| Evolus Inc | -1.260% | -3.871% | -15.000% | -34.208% | -7.046% | -44.330% | -42.757% |
| Heron Therapeutics Inc. | 0.230% | 2.964% | 15.931% | -70.432% | -61.329% | -70.694% | -95.846% |
| Rhythm Pharmaceuticals | 0.000% | -5.000% | -11.856% | 14.765% | -8.556% | 437.736% | 493.750% |
Comments
Karyopharm Therapeutics (KPTI) had its price target lowered by Piper Sandler from $16.00 to $7.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (KPTI) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Show more
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (KPTI) had its "buy" rating reaffirmed by HC Wainwright.
Show more
Ratings data for KPTI provided by MarketBeat
News
Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts
Key Points
- Interested in Karyopharm Therapeutics Inc.? Here are five stocks we like better.
- Karyopharm highlighted upcoming milestones for selinexor, including an ASCO late-breaking
Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus
Key Points
- Interested in Karyopharm Therapeutics Inc.? Here are five stocks we like better.
- Karyopharm said it will present fuller Phase 3 SENTRY data for selinexor in newly diagnosed
Karyopharm Therapeutics Q1 Earnings Call Highlights
Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in